Metformin use may be associated with decreased risk of prostate cancer
the ONA take:
According to a new study published in the journal European Urology, researchers have found that metformin use was associated with a decreased risk of prostate cancer diagnosis while other oral antihyperglycemics had no decreased risk.
For the nested case-control study, researchers identified 12,226 cases of prostate cancer among men residing in Northern Denmark between 1989 and 2011 from the Danish Cancer Registry and the Aarhus University Prescription Database.
They found that compared with never-users of metformin, metformin users had a decreased risk of prostate cancer diagnosis (adjusted OR = 0.84, 95% CI: 0.74 - 0.96). In addition, diabetics on no antihyperglycemics (adjusted OR = 0.98, 95% CI: 0.89 - 1.09) or on oral antihyperglycemics other than metformin (adjusted OR = 0.98, 95% CI: 0.86 - 1.10) did not have a decreased risk of prostate cancer. Insulin users also had a decreased risk of prostate cancer (adjusted OR = 0.77, 95% CI: 0.64 - 0.93).
Furthermore, among patients who had prostate-specific antigen (PSA) testing prior to 1 year before being indexed, metformin users had a decreased risk of prostate cancer versus nonusers (adjusted OR = 0.66, 95% CI: 0.51 - 0.86). In the same PSA-tested group, diabetics on no medication, other oral antihyperglycemics, or insulin did not have a significant reduced risk of the disease.
Metformin use associated with decreased risk of prostate cancer diagnosis.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- A Witness to Letting Go: Nursing Care at the End of Life
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Intervention Improves Breast Cancer Survivors' Memory Contentment
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Patients With Head and Neck Cancer Have Greater Chance of Being Prescribed Opioids
- Medical Terms in Patient Education: Using the Confusing to Explain the Complicated
- Bedside Assessment Tool Improves Worst Pain in Patients With Cancer
- Androgen-Deprivation Therapy for Prostate Cancer May Cause Nocturia, Sleep Disturbance
- USPSTF Rates Ovarian Cancer Screening a D for Asymptomatic, Low-Risk Women
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|